← Back to Search
Tyrosine Kinase Inhibitor
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
Irvine, CA
Phase 2
Waitlist Available
Research Sponsored by Dermavant Sciences GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 15, 29 and 43
Summary
This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo
Eligible Conditions
- Vitiligo
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 1, 15, 29 and 43
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 15, 29 and 43
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Laboratory Values
Local Tolerability Scale Score
+1 moreSecondary study objectives
Blister fluid biomarker concentration
Concentration of cerdulatinib
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cerdulatinib 0.37% gelExperimental Treatment1 Intervention
Cerdulatinib 0.37% gel applied topically twice daily
Group II: Vehicle gelPlacebo Group1 Intervention
Vehicle gel applied topically twice daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cerdulatinib
Not yet FDA approved
Find a Location
Closest Location:Dermavant Investigational Site· Irvine, CA
Who is running the clinical trial?
Dermavant Sciences GmbHLead Sponsor
12 Previous Clinical Trials
3,093 Total Patients Enrolled
Michael McLaughlinStudy DirectorDermavant Sciences GmbH
2 Previous Clinical Trials
428 Total Patients Enrolled